Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ABEO
$5.34
$
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Next Earnings
2026-02-25
Beta
1.132
Average Volume
Market Cap
Last Dividend
CIK
0000318306
ISIN
US00289Y2063
CUSIP
00289Y107
CEO
Vishwas Seshadri
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
136
IPO Date
1980-09-19
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of “Moderate Buy” from Analysts | Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 | Defense World | 2026-02-18 02:09:00 |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). | GlobeNewsWire | 2026-02-09 10:04:00 |
| Madhav Vasanthavada Sells 12,610 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock | Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) insider Madhav Vasanthavada sold 12,610 shares of the firm's stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $5.29, for a total value of $66,706.90. Following the completion of the sale, the insider directly owned 318,619 shares in the | Defense World | 2026-01-28 05:32:45 |
| Vishwas Seshadri Sells 69,832 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock | Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) CEO Vishwas Seshadri sold 69,832 shares of the firm's stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $372,204.56. Following the transaction, the chief executive officer directly owned 1,460,408 shares of the company's | Defense World | 2026-01-24 05:23:01 |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). | GlobeNewsWire | 2025-12-31 07:30:00 |
| Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of “Moderate Buy” by Brokerages | Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average | Defense World | 2025-12-30 03:18:56 |
| Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company. | GlobeNewsWire | 2025-12-15 07:30:00 |
| AWM Investment Company Inc. Acquires New Shares in Abeona Therapeutics Inc. $ABEO | AWM Investment Company Inc. bought a new position in Abeona Therapeutics Inc. (NASDAQ: ABEO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 470,000 shares of the biopharmaceutical company's stock, valued at approximately $2,670,000. AWM Investment Company Inc. owned approximately 0.92% | Defense World | 2025-12-13 03:50:57 |
| Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas | CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). | GlobeNewsWire | 2025-12-11 07:30:00 |
| Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy | CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN was administered at Lucile Packard Children's Hospital Stanford in Palo Alto, CA. | GlobeNewsWire | 2025-12-08 07:30:00 |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). | GlobeNewsWire | 2025-12-01 07:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-12 | 2026-02-12 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 3 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G | 2025-10-30 | 2025-10-30 | View Filing |
| 4 | 2025-10-16 | 2025-10-16 | View Filing |
| SC 13G/A | 2025-10-06 | 2025-10-06 | View Filing |
| SC 13G | 2025-10-06 | 2025-10-06 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| SC 13G | 2025-09-30 | 2025-09-30 | View Filing |
| 4 | 2025-09-22 | 2025-09-22 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-07-22 | 2025-07-22 | View Filing |
| 8-K | 2025-07-18 | 2025-07-18 | View Filing |
| SC 13G | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13G/A | 2025-05-01 | 2025-05-01 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-09 | 2025-04-09 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-01-31 | 2025-01-31 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-21 | 2025-01-21 | View Filing |
| S-8 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| DEF 14A | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-10-29 | 2024-10-29 | View Filing |
| 4 | 2024-10-17 | 2024-10-17 | View Filing |
| SC 13G/A | 2024-10-08 | 2024-10-08 | View Filing |
| 4 | 2024-09-30 | 2024-09-30 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 28.23% | 1.01 | 217 | 0.03 | 0.06 | 29.45 |
| Williams PercentR Strategy | 27.21% | 1.01 | 398 | 0.02 | 0.07 | 28.43 |
| Neural Forcast | 25.34% | 1 | 839 | 0.02 | 0.04 | 26.56 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |